HOOKIPA Pharma Inc., a company developing a new class of immunotherapies based on its proprietary arenavirus platform, and Roche formed a strategic collaboration and license agreement to develop HB-700 for KRAS-mutated cancers, along with a second undisclosed novel arenaviral immunotherapy. This represents HOOKIPA’s first oncology licensing collaboration.
As we mark Lung Cancer Awareness Month, it is a time to acknowledge that screening and prevention are vital, and equally crucial is ensuring that patients have access to state-of-the-art care and research. Herein, I spotlight some of the transformative work underway at City of Hope.
